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DOI 10.1016/j.immuni.2011.02.004SUMMARY Ly-6G-/lowLy-6Chigh monocytic MDSCs, have been describedMyeloid-derived suppressor cells (MDSCs) bear
characteristics of precursors for both M1 and M2
macrophages. The molecular mechanism underlying
the differentiation into M1 and M2 macrophages and
the relationship of this differentiation to antitumor
responses remains largely undefined. Herein, we
investigate the potential function of paired immuno-
globulin-like receptor B (PIR-B), also known as
leukocyte immunoglobulin-like receptor subfamily
B member 3 (LILRB3) in MDSC differentiation, and
its role in tumor-induced immunity. Our studies indi-
cated that MDSCs genetically ablated for PIR-B
(Lilrb3/) underwent a specific transition to M1-like
cells when entering the periphery from bone marrow,
resulting in decreased suppressive function, regula-
tory T cell activation activity, primary tumor growth,
and lung metastases. Activation of Toll-like receptor
(TLR), signal transducers, and activators of tran-
scription 1 (STAT1), and nuclear factor-kappa B
(NF-kB) signaling in Lilrb3/ MDSC promoted the
acquisition of M1 phenotype. Inhibition of the PIR-B
signaling pathway promoted MDSC differentiation
into M1 macrophages.
INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) play an important
role in tumor-induced immune tolerance. In tumor-bearing
animals and cancer patients, MDSCs accumulate in lymphoid
organs such as the spleen and bone marrow, as well as within
the tumor, and throughout the peripheral blood circulation (Ser-
afini et al., 2006). These cells were originally identified with the
phenotype of Gr-1+CD11b+ (Serafini et al., 2004). Recently,
two distinct subpopulations, Ly-6G+Ly-6Clow granulocytic and(Peranzoni et al., 2010; Movahedi et al., 2008; Youn et al.,
2008). Functionally, MDSCs suppress T cell responses through
productions of inducible nitric oxide synthase (iNOS) and argi-
nase 1 (ARG1), which are induced upon stimulation with inter-
feron-g (IFN-g) and interleukin-4 (IL-4) or IL-13, respectively
(Kusmartsev et al., 2000; Sinha et al., 2005c; Sinha et al.,
2005b; Huang et al., 2006; Marigo et al., 2008). More recently,
we showed that CD115+Gr-1+Ly6Chi monocytic MDSCs
promoted regulatory T cell (Treg cell) induction and expansion
in tumor bearing mice (Huang et al., 2006).
In the tumor microenvironment, tumor associated macro-
phages (TAMs) constitute the majority of tumor-infiltrating leuko-
cytes. Two distinctive TAM sub-populations have been defined.
Classical, or M1, macrophages are characterized by the expres-
sion of high amounts of iNOS and tumor necrosis factor-a
(TNF-a), whereas alternatively activated M2 macrophages typi-
cally produce ARG1 and IL-10 (Umemura et al., 2008). At the
tumor site in wild-type mice, TAMs are predominantly M2-like
macrophages, which are the cells primarily responsible for sup-
pressing T cell-mediated antitumor responses and promoting
tumor progression, metastasis, and angiogenesis (Guruvayoor-
appan, 2008; Mantovani et al., 2009; Mantovani et al., 2002;
Sica et al., 2008). M1macrophages, in contrast, exhibit, a tumor-
icidal effect (Sinha et al., 2005a; Sinha et al., 2005c).
Monocytic MDSCs and TAMs share several characteristics,
such as expression of the monocyte and macrophage markers
F4/80 and CD115, as well as inducible expression of iNOS and
ARG1 (LewisandPollard, 2006;Mantovani et al., 2009) (Umemura
et al., 2008). Accumulating evidence suggests that, upon entering
tumor tissues, MDSCs may differentiate into TAMs, leading to
elevated IL-10 production, inhibition of T cell responses, and
promotion of angiogenesis (Yang et al., 2004). However, the
mechanism behind regulation of MDSC differentiation remains
unclear (Sinha et al., 2007; Kusmartsev and Gabrilovich, 2005;
Otsuji et al., 1996; Umemura et al., 2008; Yang et al., 2004).
Mouse paired immunoglobulin-like receptors (PIRs), also
known as leukocyte immunoglobulin-like receptors (LIR) or
Ig-like transcripts (ILT) in humans, are expressed onImmunity 34, 385–395, March 25, 2011 ª2011 Elsevier Inc. 385
Figure 1. M2 Phenotype Is Essential for Treg Cell Activation by
MDSCs
(A) CFSE-labeled CD4+CD25+ Treg cells from OT-II transgenic mice were co-
cultured with MDSCs from tumor-bearing mice, stimulated with 0.5 mg/ml
OT-II peptide for 3 days, and stained with Foxp3 and CD4 antibodies. Prolifer-
ation percentages are shown in the dot plot (upper panel) and histograms
(lower panel).
(B) MDSC-mediated Treg cell activation in the presence of various inhibitors
and anti-IL-10. Data shown are from representative of six reproducible exper-
iments.
Immunity
PIR-B Regulates MDSC Differentiation and Functionmacrophages, neutrophils, mast cells, and B cells (Kubagawa
et al., 1999). The PIR family includes two molecules—PIR-A
and PIR-B (the latter encoded by the gene Lilrb3). They are
type I transmembrane receptors, which bind to major histocom-
patibility complex (MHC) class I glycoproteins (Takai, 2005).
PIR-A also associates with the Fc receptor common g chain
(FcRg) at its transmembrane region. Intracellularly, the PIR-A-
FcRg complex phosphorylates immunoreceptor tyrosine-based
activationmotifs (ITAMs) anddelivers activating signals, whereas
PIR-B phosphorylates immunoreceptor tyrosine-based inhibi-
tory motifs (ITIMs) and delivers inhibitory signals (Kubagawa
et al., 1999). In PIR-B-deficient mice, hyperresponsiveness has
been observed in a variety of different cell types. In a transplanta-
tion model, PIR-B deficient mice show accelerated, lethal graft
versus host disease (GVHD) as a result of the upregulation of
PIR-A and enhancedproduction of IFN-g (Nakamura et al., 2004).
We hypothesized that PIRs may regulate MDSC function and
differentiation in the tumor environment. In the present study,
we found that in PIR-B-deficient tumor-bearing mice,
Gr-1+CD115+ monocytic MDSCs exhibited enhanced expres-
sion of iNOS and TNF-a, preferentially acquiring an M1-like
phenotype in the spleen and at the tumor site, and that tumor
growthwas significantly retarded. Furthermore, adoptively trans-
ferred MDSCs from Lilrb3/ tumor-bearing mice inhibited the
growth of pre-existing tumors and lung metastases. These func-
tional differences were correlated with upregulation of the signal
transducers and activators of transcription 1 (STAT1) and nuclear
factor-kappaB (NF-kB) signaling pathways.Our findings demon-
strated that the signaling balance between PIR-A and PIR-B is
a key factor in the regulation of MDSC differentiation into M1 or
M2 phenotypes and has an impact on MDSCs’ functions in
both immune suppression and promotion of tumor progression.
RESULTS
Treg Cell Activation Mediated by MDSCs through
M2-Associated Effector Mechanisms
We have shown that monocytic MDSCs suppress T cell prolifer-
ation directly and induce Treg cell expansion in tumor-bearing
mice (Huang et al., 2006; Pan et al., 2010). We also found that
expression of M1-associated iNOS production by MDSCs was
not required for Treg cell expansion (Huang et al., 2006). Here,
we tested whether M2-associated genes, such as ARG1 and
IL-10, were required for Treg cell expansion as mediated by
MDSCs. Whereas the addition of iNOS inhibitor did not signifi-
cantly affect antigen-specific Treg cell proliferation in the pres-
ence of MDSCs, addition of an ARG1 inhibitor, anti-IL-10, or
the use of IL-4Ra-deficient MDSCs significantly abrogated the
Treg cell expansion mediated by MDSCs (Figures 1A and 1B;
wild-type (WT) versus ARG1 inhibitor p = 0.01, WT versus anti-
IL-10, p = 0.0016;WT versus Il-4ra/, p = 0.0012). This indicates
that M2-associated effector mechanisms employing IL-10 and
IL-4 or IL-13-dependent ARG1 are required for enhancement
of MDSC-mediated Treg cell proliferation.
Distinct Phenotypes between MDSCs from Marrow
and Those from Spleen of Lilrb3–/– Tumor-Bearing Mice
To determine whether PIR-B is involved inMDSC-mediated Treg
cell activation, we utilized WT and Lilrb3/ Lewis lung carci-386 Immunity 34, 385–395, March 25, 2011 ª2011 Elsevier Inc.noma (LLC) tumor-bearing mice. Monocytic MDSCs were puri-
fied separately from bone marrow and spleen of WT and
Lilrb3/ tumor-bearing mice and suppressive function was
evaluated. MDSCs from the bone marrow of WT and Lilrb3/
tumor-bearing mice both suppressed OTII T cell proliferation
to similar degrees in response to ovalbumin (OVA) peptide
(p = 0.18) (Figure 2A), whereas splenic Lilrb3/ MDSCs had
decreased suppressive activity when compared to WT splenic
MDSCs (p < 0.05). Similarly, Treg cell induction by bone
marrow-derived MDSCs was not significantly different between
Lilrb3/ andWTMDSCs (21.5 ± 0.6 versus 21.1 ± 2.1), whereas
decreased Treg cell induction was observed when comparing
Lilrb3/ to WT splenic MDSCs, (6.0 ± 0.5 versus 10.7 ± 0.6,
p < 0.001) (Figure 2B).
On the basis of these results, we hypothesized that MDSC
function and differentiation may be regulated by PIR-B, espe-
cially once MDSCs migrate from the bone marrow to peripheral
lymphoid organs and the tumor microenvironment. We also
compared phenotypic differences between MDSCs from WT
and Lilrb3/ mice. In WT tumor-bearing mice, splenic MDSCs
Figure 2. Lilrb3–/– Splenic MDSCs but Not Bone Marrow-Derived
MDSCs Exhibit an M1 Phenotype
(A) Suppression assay with various ratios of MDSCs from tumor-bearing WT
and Lilrb3/ bone marrow (left) and spleen (Right). Coculture with spleno-
cytes from naive OT-II transgenic mice, stimulated with OT-II peptide, is
shown. Proliferation count per minute: CPM 3 1000. Bars and SD from tripli-
cate wells are shown (*p < 0.05).
(B) WT and Lilrb3/ MDSCs from bone marrow and spleen were cocultured
with OT-II splenocytes at a 1:4 ratio for 5 days and subsequently stained
with CD4, CD25, and Foxp3 antibodies. The CD4+ cell population was gated
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PIR-B Regulates MDSC Differentiation and Functionexhibited a higher ARG1 activity (p < 0.001) and IL-10 (p < 0.01)
secretion but a lower iNOS activity (p < 0.001) and TNF-a secre-
tion (p < 0.001), suggesting MDSCs preferentially differentiate
into an M2-like phenotype in WTmice and anM1-like phenotype
in Lilrb3/ mice (Figure 2C). Lilrb3/ splenic MDSCs ex-
pressed lower quantities of the M2 markers CD36, CD206,
Tie2, and CCR2 but higher amounts of the M1 marker CCR7
than WT MDSCs (Figures 2D and 2E). We also measured inter-
feron-g receptor (IFN-gR) and interleukin-4 receptor (IL4-R)
expression, whose signaling promotes M1 and M2 polarization,
respectively. IL-4R expression was lower, whereas IFN-gR was
higher in Lilrb3/ MDSCs (Figure 2D). Although no differences
in IL-10R expression were observed between WT and Lilrb3/
MDSCs (Figure 2D), significantly lower IL-10 expression by
Lilrb3/ MDSCs could account for the M1-oriented phenotype
(Figure 2C). However, this difference was not observed with
bone marrow-derived MDSCs (Figure S1A available online).
MDSCs isolated from tumor-bearing Lilrb3/ mice also lost
their ability to induce Treg cells and suppress T cell proliferation
in vivo in OT-II transgenic mice (Figure S1B).
These results indicate Lilrb3/MDSCs favor an M1, over M2,
phenotype upon exiting the bone marrow in tumor-bearing
mice. To determine whether myeloid growth and differentiation
factors, such as macrophage colony stimulating factor (M-CSF)
and granulocyte-macrophage colony stimulating factor
(GM-CSF), could dictate macrophage polarization in vitro, we
cultured Gr-1+CD115+ monocytes purified from bone marrow
and spleen of Lilrb3/ or WT naive mice in the presence of
M-CSF or GM-CSF. In the presence of M-CSF, both bone
marrow and splenic Lilrb3/ monocytes preferentially under-
went M1-like differentiation, expressing significantly higher
amounts of iNOS and TNF-a, with decreased arginase and
IL-10 production, when compared to WT monocytes (Fig-
ure S1C). With GM-CSF, Lilrb3/ bone marrow monocytes
produced significantly more iNOS and TNF-a, whereas no
difference was found in ARG1 and IL-10 production (Fig-
ure S1D). These results suggest preferential acquisition of an
M1-like phenotype by naive Lilrb3/ monocytes. Furthermore,
M-CSF may play a role in polarization of WT macrophages to
both M1 and M2 phenotypes whereas GM-CSF may only
promote the M1-oriented phenotype.
Retarded Tumor Growth andMDSCswithM1 Phenotype
in Lilrb3–/– Tumor-Bearing Mice
Because in vivo suppressive functions of Lilrb3/MDSCs were
weaker than WT, we examined whether PIR-B deficiency hasto show Treg cell percentages. Data presented are from one of seven repro-
ducible experiments.
(C) Lilrb3/ splenic MDSCs exhibit an M1 phenotype. Splenic MDSCs from
WT or Lilrb3/ tumor-bearing mice were cultured in culture media in the
absence of any stimulation for 24 hr. Arginase activity and IL-10, NO, and
TNF-a production in the culture supernatant were measured.
(D) Purified splenic MDSCs were stained for scavenger receptor B (CD36),
mannose receptor (CD206), IL-4R, Tie2, PDL1, CD80, CD86, MHC class II,
and CC7. Expression was evaluated in the Gr-1+CD115+ cell population.
Colored lines correspond to the following: gray line, isotype control; blue
line, wild-type MDSC; and red line, Lilrb3/ MDSC. Data was from one of
three reproducible experiments. (E) Real time PCR for CCR7 and CCR2
expression with GAPDH internal control (*p < 0.05; **p < 0.01; ***p < 0.001).
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Figure 3. Lilrb3–/– Tumor Environment Retards Tumor Growth and
Gives Rise to M1-Polarized MDSCs
(A) LLC tumor was implanted subcutaneously in WT or Lilrb3/ mice (n = 6)
and tumor size was measured every 6 days for 30 days. *p < 0.05; **p < 0.01.
(B) Real-time quantitative PCRwas performed onGr-1+CD115+MDSCs isolated
from TILs. Relative copy number was calculated based on b-actin. The black
column showsWT TIL MDSCs, and the white column shows Lilrb3/ TIL
MDSCs.Datapresented is fromone of four reproducible experiments, **p < 0.01.
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388 Immunity 34, 385–395, March 25, 2011 ª2011 Elsevier Inc.any impact on tumor growth. The rate of tumor growth was
significantly slower in Lilrb3/ mice compared with WT mice
over time (Figure 3A). To determine whether this effect was
correlated with the anti-tumor M1 phenotype observed in
Lilrb3/ MDSCs, we directly isolated MDSCs from these
tumors. Tumor-infiltrating Lilrb3/ MDSCs expressed signifi-
cantly higher amounts of iNOS (p < 0.05), TNF-a (p < 0.01),
IL-12 (p < 0.01), and IL-1-b (p < 0.01) and significantly lower
amounts of ARG1 (p < 0.01) and IL-10 (p < 0.01) when compared
with WT MDSCs, as assessed by quantitative real-time poly-
merase chain reaction (PCR) (Figure 3B). We also examined
expression of several M2 surface markers, such as CD36,
CD206, Tie2, and IL-4R (Guruvayoorappan, 2008; Kodumudi
et al., 2010; Mantovani et al., 2009; Mantovani et al., 2002;
Sica et al., 2008), by flow cytometry. Lilrb3/ tumor-infiltrating
MDSCs expressed lower amounts of CD36, CD206, Tie2, and
IL-4R thanWTMDSCs (Figure 3C). These results were confirmed
by immunofluorescent staining of LLC tumor tissue (Figure 3D).
We used CCR7 as a marker for M1 macrophages and CD206
as an M2 marker with CD11b costaining to identify MDSCs.
CD206 was highly expressed in tumor tissue from WT mice,
whereas CCR7 was dominant in tumor tissue from Lilrb3/
mice. Both markers colocalized with CD11b+ myeloid cells, indi-
cating that MDSCs in WT tumor-bearing mice had an M2 pheno-
type, whereas those from Lilrb3/mice bore more resemblance
to M1macrophages. These observations were further confirmed
by assessment of the macrophage marker F4/80 and iNOS (M1)
and ARG1 (M2) expression.
Sorted Lilrb3/ MDSCs isolated directly from tumor infil-
trating leukocytes (TILs) also had higher direct cytolytic activity
against parental tumor cells than MDSCs isolated from WT
mice (Figure 3E). This suggests that Lilrb3/ MDSCs in the
tumor exhibit an M1-like phenotype, express higher quantities
of proinflammatory cytokines, and possess direct cytolytic func-
tion, suggesting they might have tumor-killing activities.
BecauseM1macrophages have been shown to exhibit tumor-
icidal activities (Sinha et al., 2005b), we assessed the therapeutic(C) TILs fromWT or Lilrb3/ tumor tissue were stained for Gr-1, CD115, CD36,
CD206, Tie2, and IL-4R. Expressions of these proteinswere compared via histo-
gram. Colored lines and their corresponding items are as follows: gray line, iso-
type control; blue line, WT MDSC; and red line, Lilrb3/MDSC. Data shown re
from one of four reproducible experiments.
(D) CD11b (green), CD206 (yellow), CCR7 (red), and DAPI (blue) or F4/80 (green),
ARG1 (yellow), iNOS (red), and DAPI (blue) immunofluorescent staining of LLC
tumor tissues fromWT or Lilrb3/mice. CD11b, CD206, and CCR7 were colo-
calizedwithDAPI separately ormerged, and four specimens per group per stain-
ing combination were examined.
(E) Tumor cytotoxicity mediated by monocytic MDSCs. Tumor-killing activities
were measured as percentage of tumor cell death. Data shown are from one of
four reproducible experiments.
(F) Effect of adoptive cell transfer of MDSC on subcutaneous LLC tumor growth.
Student’s t test was performed by comparison of the MDSC transfer group with
without MDSC adoptive transfer control group (*p < 0.05, **p < 0.01).
(G) The effect of MDSC adoptive transfer on lung metastasis. The left panel
shows the long-term survival rate of treated mice. The right panel shows the
lung weight. The survival rate of mice receiving Lilrb3/ MDSCs is significantly
higher than that of mice injected with WT MDSC (log-rank test, p = 0.0036). On
day 25, representative mice were sacrificed and lung weights were measured.
Lungs frommice receivingLilrb3/MDSCsweighedsignificantly less than those
frommice receiving PBS or WTMDSC (**p < 0.01).
Figure 4. PIR-B Is Essential for MDSC-Mediated
Treg Cell Expansion, Immune Suppression, and
Tumor Promotion
OVA-LLC-bearing MaFIA mice (CD45.2) were left
untreated or depleted of CD115+ cells; this process was
followed by adoptive transfer of CD45.1 OT-II T cells and
reconstitution with WT or Lilrb3/ MDSCs.
(A) Tumor (OVA)-specific CD4+CD25+Foxp3+ Treg cells in
the tumor and spleen. TILs were isolated and stained with
antibodies against CD45.1, CD4, CD25, and Foxp3 or iso-
type controls and then analyzed with flow cytometry.
Contour plots were gated on the CD45.1+CD4+ popula-
tion. One of three reproducible experiments (n = 6–7 per
group) is presented.
(B) Percentage of tumor (OVA)-specific Treg cells in the
tumor (fourth versus third column) (C) Tumor weight.
Tumors were resected from tumor-bearing mice and
weighed (fourth versus third column,). Data were
combined from three reproducible experiments (n = 6).
(D) Proliferative response of tumor (OT-II)-specific T cells
from recipient MaFIA mice. CD45.1+ OT-II T cells were re-
isolated from the spleen of recipient mice and stimulated
with OVA peptide (1 mg/mL) in the presence of irradiated
naive splenocytes for 3 days. Cells were pulsed with
[3H]-thymidine for the last 8 hr of culture (fourth versus
third column, **p = 0.003).
(E) Tumor vascularity assessed by immunofluorescent
CD31 (red) staining with DAPI (blue) background in
OVA-LLC tumors from mice that received injections of
WT or Lilrb3/ MDSCs.
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taneous and lung metastases tumor models. Upon adoptive
transfer, Lilrb3/ Gr-1+CD115+ monocytic MDSCs significantly
retarded the growth of subcutaneous tumors (Figure 3F, p =
0.014 on day 35), prolonged survival rate (Figure 3G, left
panel, p = 0.0036), and inhibited lung metastases in recipient
mice (Figure 3G, right panel, p < 0.001). Interestingly, neither
WTmonocytic MDSCs nor Lilrb3/ Ly6G+ granulocytic MDSCs
exerted significant effects on tumor growth or lung metastases
when compared to control mice that did not receive adoptive
cell transfer.
We next attempted to elucidate the mechanisms underlying
the retarded tumor growth and enhanced antitumor responses
in Lilrb3/ tumor-bearing mice. MaFIA (macrophage Fas-
induced apoptosis) mice, whose endogenous CD115+ mono-
cytic MDSCs are tagged with green fluorescent protein and
can be depleted through the use of crosslinking reagent
AP20187 (Pan et al., 2010), were chosen. CD45.1 OT-II T cells
were adoptively transferred into MaFIA mice with pre-existing
OVA-LLC tumors andCD115+ cells were subsequently depleted,Immunity 34, 3with and without reconstitution with CD115+
monocytic MDSCs derived fromWT or Lilrb3/
tumor-bearingmice. Ten days after the adoptive
transfer, tumor-infiltrating leukocytes (TILs) and
splenocytes were stained for CD45.1+CD4+-
CD25+Foxp3+ antigen-specific Treg cells. In
the CD115+-depleted group, significant
decreases in the Treg cell population (Figures
4A and 4B, p < 0.001) and tumor weight (Fig-
ure 4C, p < 0.001), and significantly increasedproliferation of antigen-specific T cells (Figure 4D, p < 0.001)
were observed. In the WT MDSC adoptive transfer group, the
presence of MDSCs compensated for the depletion of CD115+
cells leading to expansion of the Treg cell population, increases
in tumor weight, and suppression of antigen-specific T cell
responses, similar to the mock depletion control group. Interest-
ingly, the Lilrb3/ MDSC adoptive transfer group had signifi-
cantly fewer Treg cells in the TIL population (Figures 4A and
4B; p < 0.001 in TIL), and spleen (p = 0.022, data not shown),
lower tumor weights (Figure 4C; p = 0.01), and strong
antigen-specific T cell proliferation (Figure 4D; p = 0.003),
when compared with mice that had received WT MDSCs. The
results were similar to those of the CD115-depleted MaFIA
mice that were not reconstituted with MDSCs, indicating that
MDSCs from Lilrb3/ mice cannot suppress antitumor
immunity within the tumor microenvironment. Because M2
macrophages promote tumor angiogenesis, we evaluated the
vasculature of tumors from the mice that received WT or
Lilrb3/ MDSC by immunofluorescent staining. Tumor tissue
from the WT MDSC transfer group exhibited more prominent85–395, March 25, 2011 ª2011 Elsevier Inc. 389
Figure 5. PIR-B Regulates M1 versus M2 Polarization in MDSCs
through Jak/STAT and TLR Pathways
(A, C, and D)Western blots were performedwithMDSCs stimulated with IFN-g
(50 ng/ml), IL-10 (50 ng/ml), IL-13 (50 ng/ml), or LPS (100 ng/ml) for 10 and
Immunity
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390 Immunity 34, 385–395, March 25, 2011 ª2011 Elsevier Inc.vascularity, as demonstrated by increased CD31 staining,
compared to tissues from the Lilrb3/ MDSC transfer group
(Figure 4E).
Effect of PIR-B Deficiency on STAT and Toll-like
Receptor Signaling
Lilrb3/ mice exhibit hyperresponsive B cells, neutrophils,
macrophages, and mast cells, which can be attributed to the
failure to recruit the tyrosine phosphatase SHP-1, which delivers
constitutive inhibitory signals to janus kinase (JAK)-STAT path-
ways (Blanchette et al., 2009; David et al., 1995; Dong et al.,
2001). In Lilrb3/MDSCs, phosphorylation of STAT1 was upre-
gulated, whereas phosphorylation of STAT3 was significantly
decreased upon IL-10 stimulation. This effect is even more
profound in the presence of STAT1-activating cytokines, such
as IFN-g, or STAT3-activating cytokines, such as IL-10 (Figures
5A and 5B). These differences were also observed under inflam-
matory conditions. We also examined the Toll-like receptor 4
(TLR4) pathway, which has been shown to play a role in M1
macrophage differentiation (Mantovani et al., 2004; Martinez
et al., 2008). Lilrb3/ splenic-derived MDSCs demonstrated
increased phosphorylation of extracellular signal-regulated
kinases (ERKs), p38 mitogen-activated protein kinase (MAPK),
and NF-kB upon lipopolysaccharide (LPS) stimulation, with
minimal response to IL-13-mediated stimulation as measured
by STAT6 phosphorylation (Figures 5C and 5D). Therefore, in
the absence of functional PIR-B, TLR4 and IFN-g inflammatory
responses were upregulated. The enhanced TLR4 and IFN-g
signaling suppressed STAT3 activation and pushed Lilrb3/
MDSC toward M1 polarization.
Preferential M1 Polarization of MDSCs upon Blockade
of PIR-B Signaling with SHP1 and 2 Inhibitor
Normally, PIR-A and PIR-B are expressed simultaneously on
myeloid cells and the specific equilibrium maintained in different
cell lineages may be determined by cell activation status (Kuba-
gawa et al., 1999; Tun et al., 2003). PIR-A and PIR-B expression
were assessed quantitatively by real-time PCR. Low expressions
of PIR-A and PIR-B were detected in WT MDSCs isolated from
the bone marrow of tumor-bearing mice. Both PIR-A and PIR-
B were induced in splenic WT MDSCs, with PIR-B expression
three times greater than PIR-A (Figure 6A). Interestingly, splenic
Lilrb3/MDSCs expressed a significantly higher amount of PIR-
A compared to WT MDSCs. Surface expression of PIR was as-
sessed by flow cytometry with a currently available antibody
that recognizes both PIR-A and PIR-B. As anticipated, because
of the lack of PIR-B, weaker staining was observed in splenic
Lilrb3/ Gr-1+CD115+ MDSCs from naive mice compared to
WT splenic MDSCs (Figure 6B). Surprisingly, a similar mean30min. Mean gray value wasmeasured by ImageJ 1.43, and relative activation
is calculated by dividing phospho-protein by total protein or b-actin (*p < 0.05,
**p < 0.01).
(B) Purified MDSCs were treated with IFN-g (50 ng/ml) or IL-10 (50 ng/ml) for
10 min, and this was followed by intracellular phosphorylation staining of
p-STAT1 and p-STAT-3. The thin line refers to isotype control, the gray line
refers to WT MDSC, and the black line refers to Lilrb3/ MDSC. MFI were
calculated (second versus first column, *p = 0.030, fourth versus third column,
**p = 0.005), Data shown are from one of five reproducible experiments.
Figure 6. Upregulation of PIR-A in Lilrb3–/– MDSCs, and Regulation
of MDSC Polarization by PIR-B Blockade
(A) Real-time quantitative PCR results for PIR-A and PIR-B. Relative copy
numbers were calculated in relation to b-actin. The black column shows WT
Immunity
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MDSCs isolated from tumor-bearing mice, indicating that PIR-
A was increased in splenic Lilrb3/MDSCs from tumor-bearing
mice compared to their WT counterparts or splenic Lilrb3/
MDSCs isolated from naive mice. Therefore, in the presence of
chronic inflammation, such as tumor-derived signals, PIR-B
may inhibit PIR-A expression; however in the absence of PIR-B
signaling, PIR-A may compensate for the lack of PIR-B, resulting
in PIR-A being the dominant activation signal.
SHP-1 is an important downstream mediator of PIR-B
signaling. To confirm the relationship between downstream
PIR receptor signaling and macrophage differentiation, we
tested whether the SHP-1 and SHP-2 inhibitor NSC 87877 could
inhibit normal PIR-B function in MDSCs. MDSCs treated with
NSC 87877 exhibited a phenotype similar to Lilrb3/ MDSCs.
Significant decreases in ARG1 and IL-10 production were
observed both in the presence and absence of IL-13 (Figure 6C).
We also used SHP-1 mutant motheaten viable (mev) mice
to confirm that SHP-1 was involved in the control of MDSC
differentiation as mediated by PIR-B. As with the results
obtained with the SHP-1 and SHP-2 inhibitor (Figure 6C),
SHP-1 mutated mev MDSCs exhibited an M1-oriented pheno-
type (Figure 6D).
MHC class I is one of the putative ligands for both PIR-A and
PIR-B (Takai, 2005). Therefore, we examined the phenotype of
MDSCs isolated from b2 microglobulin (b2 m)-deficient (hence
MHC class I deficient) tumor-bearing mice. MDSCs from these
mice had a similar phenotype to WT MDSCs when exposed to
IFN-g or IL-13 stimulation (Figure 6C), possibly because of
the lack of both positive and negative signaling of PIR. Upon
crosslinking with PIR-A and -B antibodies (6C1), WT MDSCs
acquired an M2 phenotype, i.e., decreased NO and TNFa
production, and increased ARG1 and IL-10 production. This
result would be consistent with the M2-oriented phenotype of
WT MDSCs isolated from tumor-bearing mice. However, no
significant increase in NO and TNFa production was observed
in Lilrb3/ MDSCs in the presence of 6C1, possibly because
of high basal productions of NO and TNFa (Figure S2, p >
0.05), consistent with the M1-oriented phenotype of Lilrb3/
MDSCs. Meanwhile, IL-10 secretion was significantly decreased
in Lilrb3/ MDSCs upon triggering with 6C1 (Figure S2, p <
0.001).MDSCs, and the white column shows Lilrb3/ MDSCs. Data shown is from
one of two reproducible experiments.
(B) Splenocytes from naive or tumor-bearing mice were stained with Gr-1,
CD115, and PIR-A and -B antibodies, which stains both PIR-A and PIR-B.
Expressions of PIR-A and -B were compared by gating on the Gr-1+CD115+
MDSC population. The thin line refers to isotype control, the gray line refers
to wild-type MDSC, and the black line refers to Lilrb3/ MDSC. Data shown
are from one of four reproducible experiments.
(C) MDSCs from WT, Lilrb3/, and b2m-deficient tumor-bearing mice or WT
MDSC treatedwith NSC 87877 (SHP inhibitor) were cultured in the presence or
absence of IL-13 or IFN-g (50 ng/ml) for 24 hr. INOS and ARG1 activity and
TNFa and IL-10 production in supernatant were measured by colorimetric
assay and ELISA, respectively (*p < 0.05, **p < 0.01).
(D) MDSCs from SHP-1 mutated mev/mev tumor-bearing mice had an M1
phenotype, whereas FcRg-deficient MDSCs had an M2 phenotype. Gr-
1+CD115+ MDSCs were purified fromWT, Lilrb3/,mev/mev, and FcRg-defi-
cient tumor bearing mice. ARG1 activity, NO production, and IL-10 and TNF-a
secretion were measured by colorimetric assay and ELISA, respectively.
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analyzed the macrophage polarization of MDSCs isolated from
Fcer1g/ tumor-bearing mice. Consistent with our hypothesis
and data from PIR-B deficient mice, Fcer1g/ Gr-1+CD115+
MDSCs were M2 oriented and associated with a higher ARG1
and IL-10 production, increased CD36 and CD206 expression,
and lower iNOS, TNFa, and CCR7 expression (Figure 6D).
Taken together, our results demonstrated that PIR-B plays an
important role in the regulation of functions and differentiation of
MDSCs. In Lilrb3/ MDSCs, TLR4 and IFN-g signaling was
heightened whereas STAT3 signaling was suppressed, the
combination of which leads to M1 polarization. The M1 pheno-
type of Lilrb3/MDSCs correlated with retarded tumor growth,
enhanced anti-tumor responses and decreased Treg cell
activation.
DISCUSSION
Monocytic MDSCs express myeloid precursor markers. Studies
have shown that they possess a phenotype containing elements
of both M1 and M2 macrophages. However, upon entering the
tumor environment, MDSCs appear to polarize toward an M2
phenotype as a result of the presence of high amounts of M2
cytokines such as IL-4 and IL13 (Gordon and Martinez, 2010;
Umemura et al., 2008). The mechanism behind MDSC differenti-
ation and the signals that control this commitment and biological
function in tumor-bearing hosts are not well understood. In this
study, we found that MDSCs are immature macrophage precur-
sors, which have the potential to differentiate into both the M1
and M2 phenotypes. This switch can be regulated through
PIR-B signaling as the cells migrate from the bone marrow into
peripheral organs.
We demonstrated that MDSCs from Lilrb3/ mice exhibit an
M1, rather than M2, phenotype in the tumor environment. The
M1 propensity of Lilrb3/ MDSCs is intrinsic and not affected
by cytokine profile in the tumor microenvironment because the
tumors from Lilrb3/ mice had higher amounts of IL-4 and
IL-13 than those from wild-type mice (data not shown). Splenic
MDSCs from Lilrb3/ mice also exhibit an M1 phenotype and
diminished immune suppression, as well as Treg cell-activating
ability. This phenomenon was not observed in bone marrow-
derived MDSCs, indicating that in order for this phenotypic
switch to occur, MDSCs must receive specific signals leading
to a state of differentiation and maturity, which is not attainable
within the bone marrow environment. We found that Lilrb3/
MDSCs expressed significantly higher amounts of PIR-A in
tumor-bearing, but not naive animals. PIR-A signaling may be
inhibited by PIR-B, suggesting that in an inflammatory environ-
ment, such as that found in tumor-bearing mice, PIR-B may
dominantly regulate MDSC polarization. Constitutive cis binding
between PIR-B and MHC class I on mast cells plays an essential
role in the regulation of allergic responses (Masuda et al., 2007).
Therefore, the MHC class I expression on Gr-1+CD115+ MDSCs
may regulate the activation of PIR-A and PIR-B. When
comparing the difference in MHC class I expression between
bone marrow-derived and splenic Gr-1+CD115+ MDSCs, we
found that splenic, but not bone marrow-derived, PIR-B-defi-
cient MDSCs expressed a higher amount of MHC-I molecules
than their wild-type counterparts. This is consistent with our392 Immunity 34, 385–395, March 25, 2011 ª2011 Elsevier Inc.hypothesis that in the absence of PIR-B signaling, splenic
Lilrb3/MDSCs have the propensity to acquire an M1 oriented
phenotype because of cis binding of MHC class I to PIR-A.
Recently, other ligands such as the Staphylococcus aureus has
been reported to activate PIR signal (Nakayama et al., 2007),
which indicates MHC class I is not the exclusive ligand of
PIRs. PIR signaling may also be triggered by different ligands,
which need be further investigated.
Differentiation of macrophages to the M1 phenotype depends
on activation of the TLR4 and IFN-g pathways, which in turn acti-
vate the ERK, NFkB, and STAT1 pathways. Meanwhile, M2
differentiation depends on activation signals from IL-10, IL-13,
and IL-4, which activate the STAT3 and STAT6 pathways (Man-
tovani and Sica, 2010; Mantovani et al., 2002). NF-kB and STAT1
signaling suppresses the activation of STAT3 and STAT6, while
activations of STAT3 and STAT6 inhibit NF-kB and STAT1
signaling (Mantovani and Sica, 2010). Interestingly, the inhibitory
signaling of PIR-B can suppress the activation of STAT1, STAT3,
and STAT6, whereas PIR-A signaling mainly activates the NF-kB
and ERK pathways (Hu et al., 2007; Kubagawa et al., 1999).
The counterbalance of numerous activating and inhibitory
factors will ultimately influence the differentiation of MDSCs
toward the M1 or M2 phenotype. The activation state is depen-
dent on the cytokine milieu present within the inflammatory envi-
ronment. Because IL-10, IL-13, and IL-4 are constitutively ex-
pressed and are the predominant cytokines present in the
tumor-bearing host, STAT3 and STAT6 are activated, subse-
quently activating PIR-B and SHP-1 and leading to the inhibition
of STAT1. SHP-1 can also inhibit ERK phosphorylation (Nakata
et al., 2011), thereby inhibting NF-kB (p65) phosphorylation
(Chen and Lin, 2001). A lack of inhibitory signaling from PIR-B re-
sulted in the activation of PIR-A in MDSCs, leading to the activa-
tion of the NF-kB and ERK signaling pathways. The combined
effect of activation of NF-kB, ERK, and STAT1 further sup-
pressed STAT3 and STAT6 activation and favored M1 differenti-
ation of MDSCs. Studies have shown that ITAM activation
signals can activate the NF-kB, ERK, and Stat1 pathways (Hu
et al., 2007; Taylor and McVicar, 1999), but that the p50 subunit
of NF-kB inhibits NF-kB activation and orchestrates M2 macro-
phage differentiation (Mantovani and Locati, 2009; Porta et al.,
2009). These previous findings correlate closely with what we
have observed and support our hypotheses.
Our previous studies suggest that MDSCs strongly activate
Treg cells in tumor-bearing animals (Huang et al., 2006; Pan
et al., 2008). In this study, we demonstrated that M2 phenotypic
MDSCs are critical for both in vitro and in vivo Treg cell activa-
tion. Lilrb3/ MDSCs favor the M1 rather than the M2 pheno-
type, which led to less antigen-specific Treg cell activation and
angiogenesis in the tumor environment in an adoptive transfer
model. Our findings may indicate an intrinsic relationship
between MDSCs and Treg cells.
Furthermore, we have analyzed both the pro- and antitumor
activities of cancer-related inflammation and how, by shifting
the balance fromM2 toM1macrophages, we can elicit a protec-
tive antitumor response. Indeed, adoptive transfer of Lilrb3/
MDSCs significantly retarded primary tumor growth, prolonged
survival rate, and inhibited lung metastasis. This implies
a possible role for therapeutic regulation of paired immunoglo-
bin-like receptors in cancer, autoimmune diseases, and
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apeutics through the inhibition of Treg cell expansion and angio-
genesis in cancer patients.
Furthermore, ILT3, the human counterpart of PIR-B, and its
soluble form, have been shown to be involved in Treg cell devel-
opment and GVHD prevention (Vlad et al., 2010). Interestingly,
peripheral blood CD14+CD16monocytes from cancer patients,
which are phenotypically equivalent to the mouse monocytic
MDSCs, expressed a higher amount of ILT3, but not ILT1 (acti-
vating receptor), when compared to the equivalent population
from normal donors (Figure S3).
The PIR signaling pathway plays an essential role in immune
suppression and activation through the regulation of MDSC-
mediated immune responses. The proper control of PIR function
may enable modulation of the innate immune response, an effect
that carries great potential for therapeutic translation.
EXPERIMENTAL PROCEDURES
Animals
Lilrb3/ mice were a gift from C.A. Lowell (University of California, San Fran-
cisco, CA) and T. Takai (Tohoku University, Sendai, Japan). MaFIA mice were
a gift from D.A. Cohen (University of Kentucky, Lexington, KY). C57BL/6 and
BALB/c mice were purchased from the National Cancer Institute (Frederick,
MD). CD4+ OVA TCR transgenic (OT-II) mice were a gift from J.M. Blander
(Mount Sinai School of Medicine, New York, NY). SHP-1 mutant mev/mev
mice, b2 m-deficient mice, and FcRg-deficient mice were purchased from
Jackson Laboratory (Bar Harbor, ME). All animal experiments were conducted
in accordance with the animal guidelines of the Mount Sinai School of
Medicine.
TregCell Isolation andCarboxy-Fluorescein Diacetate, Succinimidyl
Ester Labeling
Treg cells were isolated by a CD4+CD25+ Regulatory T Cell Isolation Kit (Milte-
nyi Biotec, Germany). In brief, CD4+ T cells were enriched from spleen by nega-
tive selection, stained with anti-CD25-PE, and conjugated with anti-PE mi-
crobeads. CD4+CD25+ cells were purified by positive selection. Treg cells
were labeled with CFSE (2 mM in PBS) at 37C for 10 min and then washed
with complete medium three times. CFSE-labeled, purified CD4+CD25+ Treg
cells were cultured withMDSCs, at a 4:1 ratio, in the presence of OVA peptides
(0.5 mg/ml) and IL-2 (100 U/ml) for 4 days. Proliferation (CFSE dilution) was as-
sessed by flow cytometry.
Peptides and Antibodies
OVA peptide (ISQAVHAAHAEINEAGR) was purchased from AnaSpec (Fre-
mont, CA). Mouse anti-Gr-1 allophycocyanin (APC) or fluorescein isothyocya-
nate (FITC), mouse anti-CD4 FITC, mouse anti-CD115 phycoerythrin (PE) or
APC, mouse anti-F4/80-FITC, mouse anti-CD11b-APC or FITC, mouse anti-
CD25-APC, mouse anti-Foxp3-PE, mouse anti-CD36 Alexa Fluor 647, mouse
anti-Tie2-biotin, mouse anti-CD11c FITC or PE-Cy7, and isotype-matched
mAbs were purchased from eBioscience (San Diego, CA), PE-conjugated
anti-PIR, anti-phospho STAT3 (pY705), and anti-phospho STAT1 (pY701)
were purchased from BD Biosciences (San Jose, CA), and anti-CD206-biotin
was purchased from AbD Serotec (Raleigh, NC).
Isolation of MDSC and Tumor-Infiltrating T Cells
Mice were sacrificed and the spleens, tibias, and femurs were harvested. After
lysis of red blood cells (RBCs), bone marrow cells and splenocytes were frac-
tionated on a Percoll (GE Healthcare, Piscataway, NJ) density gradient as
previously described (Huang et al., 2006). Cells banding at 40%–50% were
labeled as fraction 1, cells banding at 50%–60% were labeled as fraction 2,
and cells banding at 60%–70% were labeled as fraction 3. MDSCs were posi-
tively selected from fraction 2 by anti-CD115-PE and anti-PE microbeads (Mil-
tenyi Biotec, Auburn, CA) that include the predominant Ly6C high and some
Ly6C low population (Figure S4). TILs were isolated from tumor tissues asdescribed previously (Ozao-Choy et al., 2009) and selected as above. Cells
were sorted to >90% purity prior to use in subsequent experiments.
MDSC Suppression Assay
The suppressive activity of MDSCs was assessed in peptide-mediated prolif-
eration of TCR transgenic T cells as described previously (Huang et al., 2006).
In brief, splenocytes (13 105) from OT-II mice were cultured in the presence of
OVA peptides (1 mg/mL) and serial dilutions of irradiated (2000 rad) MDSCs in
96-well microplates. Cells were pulsed with [3H]-thymidine during the last 8 hr
of a 3 day culture.
Treg Cell Activation by MDSCs
Splenocytes (4 3 106) from OT-II mice were cultured in the presence of OVA
peptides (1 mg/mL) and irradiated (2000 rad) MDSCs (13 106) in 12-well micro-
plates. After 5-days, cells were harvested and stained with fluorochrome-
conjugated anti-CD4, anti-CD25, and anti-Foxp3 or isotype controls, after
which flow cytometry was performed.
ELISAs
Cytokine concentrations in culture supernatants were measured with mouse
IL-10 and TNFa ELISA kits (eBioscience) as per the manufacturer’s instruc-
tions. NO production wasmeasured with the Griess reagent system (Promega,
San Luis Obispo, CA) and arginase activity was measured with the Quanti-
chrom arginase assay kit (BioAssay Systems, Hayward, CA).
Cytotoxici T Lymphocyte Assay
Sorted CD115+MDSCs were isolated from tumor withMACS bead purification
(Miltenyi Biotec) and coincubated with LLC tumor cells (target cells) at 20:1 and
10:1 for 4 hr. Supernatants were collected for measurement of lactate dehy-
drogenase release (CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit,
Promega). Specific killing (in percentage) was calculated as experimental
LDH release/maximum LDH release.
Adoptive Transfer Experiments
In the OVA-LLC MaFIA tumor model, MaFIA mice (Burnett et al., 2004) were
implanted intrahepatically with OVA-LLC tumor cells. When tumors reached
7 3 7 to 9 3 9 mm2, CD115+ cells were depleted by injection of AP20187,
which crosslinks the transgenic suicide protein under the transcriptional
control of CD115 promoter and induces caspase 8-dependent apoptosis
(10 mg/kg body weight; ARIAD Pharmaceuticals, Cambridge, MA). On the
same day, sorted WT or Lilrb3/ MDSCs (5 3 106 per mouse) were injected
intravenously (i.v.). Two days after MDSC transfer, purified CD45.1+ OT-II
T cells (5 3 106 per mouse) were injected via tail vein, and this injection was
followed by a second dose of MDSCs 2 days later. Five days after the last
injection of MDSCs, mice were sacrificed. The tumor weight was measured.
The presence of tumor-specific (OT-II) Treg cells in the tumor was assessed
by flow cytometry. The proliferative response of purified splenic tumor-specific
(OT-II) CD45.1+ T cells in the presence of OVA peptides and irradiated naive
splenocytes was assessed by the standard 3H thymidine incorporation assay.
For assessment of the therapeutic effect of Lilrb3/ MDSCs, LLC tumor
cells (1 3 105) were injected subcutaneously or via the tail vein into wild-
type C57BL6 mice for establishing subcutaneous and lung metastasis
tumor models, respectively. On days 5, 10, and 15 after tumor cell injection,
5 3 106 monocytic MDSCs (Gr-1+CD115+) or granulocytic MDSCs (Ly6G+)
from wild-type or Lilrb3/ tumor-bearing mice were adoptively transferred
by tail vein injection. Tumor size was measured. In the lung metastasis model,
mice were sacrificed, and this was followed by intratracheal injection of 15%
India ink (American MasterTech). Lung tissues were harvested and washed
in water for 5 min and then fixed in Feket’s solution (70% ethanol, 3.7% form-
aldehyde, 0.75 M glacial acetic acid). Lung metastasis was assessed by the
weight of lung tissues.
Reverse Transcription-PCR and Quantitative Real-Time PCR
Target cells were homogenized in Trizol reagent (Invitrogen) and total RNAwas
extracted. DNA was digested with DNase I (Invitrogen) and reverse transcrip-
tion was performed using SuperScript III First-Strand Synthesis SuperMix for
qRT-PCR (Invitrogen). Real-time quantitative PCRwas used to determine rela-
tive quantities of mRNA (SYBRGreen PCRMaster Mix, Applied Biosystems,Immunity 34, 385–395, March 25, 2011 ª2011 Elsevier Inc. 393
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PIR-B Regulates MDSC Differentiation and FunctionFoster City, CA) with b-actin as the internal control. Primers were purchased
from Integrated DNA Technologies (Coralville, IA).
Immunostaining of Tumor Tissue
Immunostaining of LLC tumor tissues from wild-type and Lilrb3/ mice was
performed with biotinylated anti-CD206 (Abd Serotec, NC), anti-CD11b (eBio-
science, CA), anti-CCR7, anti-F4/80 (Santa Cruz biotechnology, CA), anti-
iNOS, and anti-arginase 1 (BD Biosciences, CA) and thenwith Cy3-conjugated
streptavidin, Cy2-conjugated donkey anti-rat ,and Cy5-conjugated donkey
anti-goat (Jackson ImmunoResearch,West Grove, PA) separately. Endothelial
cell staining was performed with rat anti-mouse CD31 and then with Cy3-
conjugated donkey anti-rat IgG (Jackson ImmunoResearch). Slides were
viewed with a Leica DM RA2 fluorescent microscope (Leica Microsystems,
Wetzlar, Germany) with an HC PLAN APO lens at 100 3 0.033 and 403/0.85
and Klear Mount medium (GBI, Mukilteo, WA). Images were acquired with
a Hamamatsu ORCA-ER digital camera (Minneapolis, MN) Model C4742-80-
12AG, and processed with Openlab version 5.02 (Improvision, Waltham, MA).
Western Blot Analysis
Samples were run in sodium dodecyl sulfate (SDS)-10% polyacrylamide gels
and transferred to nitrocellulose membranes. The membrane was blocked in
Superblock blocking buffer (Thermo Scientific, Rockford, IL), incubated with
an appropriate antibody, and subsequently incubated with a secondary anti-
body conjugated to horseradish peroxidase. The immunoreactive bands
were visualized with the ECL system (Thermo Scientific).
Statistical Analysis
Statistical comparisons between groups were made after presenting the data
as means with SD and then applying the Student’s t test. Survival data were
analyzed with the log-rank test. For samples with equal variance, the paired
Student’s t test for equal variance was used. For samples with unequal vari-
ance, Wilcoxian signed-rank test was used for statistical analysis. p < 0.05
was considered to be statistically significant.
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